Pharmacologic Management of Chronic Insomnia in Otherwise Healthy Adults

First‑Line Pharmacologic Recommendations (American Academy of Sleep Medicine)

• The American Academy of Sleep Medicine (AASM) recommends benzodiazepine‑receptor agonists (eszopiclone, zolpidem, zaleplon) and orexin‑receptor antagonists (suvorexant, lemborexant) as first‑line drug options for chronic insomnia in otherwise healthy adults, issuing weak recommendations because of limited evidence quality. 1

Agent‑Specific Efficacy and Evidence Strength

Benzodiazepine‑Receptor Agonists (BzRAs)

• Eszopiclone 2–3 mg improves both sleep‑onset and sleep‑maintenance insomnia, shortening sleep latency by ~15 minutes and increasing total sleep time by ~23 minutes; supported by the AASM’s first‑line recommendation (weak evidence). 1
• Zolpidem 10 mg (FDA‑approved maximum) is effective for both sleep‑onset and sleep‑maintenance insomnia with moderate‑to‑high quality evidence; doses >10 mg are off‑label and lack supporting data, and the drug carries FDA black‑box warnings for complex sleep‑related behaviors. 1
• Zaleplon 10 mg is directed at sleep‑onset insomnia but has less robust evidence compared with other BzRAs. 1

Orexin‑Receptor Antagonists

• Suvorexant 10–20 mg and lemborexant are effective for sleep‑maintenance insomnia with moderate evidence and demonstrate favorable long‑term safety profiles extending beyond 3 months. 1
• Lemborexant showed sustained efficacy in long‑term trials; safety data are promising though still somewhat inconclusive. 1

Melatonin‑Receptor Agonist

• Ramelteon 8 mg reduces sleep‑onset latency with minimal adverse effects and no dependence risk, making it suitable for patients concerned about abuse potential (evidence incorporated in AASM first‑line guidance). 1

Benzodiazepine (Second‑Line)

• Temazepam 15 mg is the AASM‑recommended benzodiazepine dose for both sleep‑onset and sleep‑maintenance insomnia; increasing to 30 mg provides no additional benefit. 1
• Triazolam 0.25 mg treats sleep‑onset insomnia but carries higher risks of dependence, falls, and cognitive impairment than BzRAs. 1

Low‑Dose Sedating Antidepressant (Second‑Line)

• Doxepin 3–6 mg selectively blocks H1 receptors, improving sleep maintenance without anticholinergic effects; it is FDA‑approved at these low doses specifically for insomnia. 1

Agents Explicitly Not Recommended (Strong Evidence Against Use)

Treatment Algorithm (American Academy of Sleep Medicine)

• Initial therapy: Choose a BzRA or orexin antagonist.

  • For predominant sleep‑onset difficulty: zolpidem 10 mg, zaleplon 10 mg, or ramelteon 8 mg.
  • For predominant sleep‑maintenance difficulty: eszopiclone 2–3 mg, suvorexant 10–20 mg, or lemborexant.
  • For combined onset + maintenance problems: eszopicone 2–3 mg or zolpidem 10 mg. 1

• If BzRAs are insufficient or contraindicated:

  • Add doxepin 3–6 mg to address sleep‑maintenance issues.
  • Consider ramelteon 8 mg for patients prioritizing non‑dependence risk.

• For refractory cases after BzRA failure:

  • Combine a BzRA with doxepin 3–6 mg.
  • Use temazepam 15 mg (not 30 mg) as a benzodiazepine alternative, with structured monitoring (monthly visits, urine screens, treatment agreements).

• Avoid escalation to non‑recommended agents such as trazodone, quetiapine, mirtazapine, or supratherapeutic zolpidem doses. 1

Safety and Duration Considerations

• FDA black‑box warnings apply to zolpidem, eszopiclone, and zaleplon for complex sleep‑related behaviors; prescribe the lowest effective dose and counsel patients on risks.
• BzRAs and benzodiazepines are approved for short‑term use (≤ 4 weeks); longer‑term use may be justified only when benefits clearly outweigh risks. 1
• Orexin antagonists may be used for ≥ 3 months with a more favorable long‑term safety profile compared with BzRAs. 1

Adjunctive Non‑Pharmacologic Therapy

• Cognitive‑behavioral therapy for insomnia (CBT‑I) should be offered alongside any medication regimen; it is the gold‑standard first‑line treatment and facilitates eventual medication discontinuation. 1
• Digital CBT‑I platforms can increase access when in‑person therapy is unavailable.

All bullet points are derived from the American Academy of Sleep Medicine 2017 guideline and are cited accordingly.

Pharmacologic Management of Refractory Insomnia After Failure of Quetiapine, Doxepin, and Trazodone

Recommended Treatment Sequence

• The American Academy of Sleep Medicine (AASM) algorithm advises that, after inadequate response to sedating antidepressants (quetiapine, doxepin, trazodone), clinicians should proceed to benzodiazepine‑receptor agonists (BzRAs) as the next line of therapy. 2, 3, 4

First‑Line Benzodiazepine Receptor Agonists (BzRAs)

• Zolpidem 10 mg reduces sleep latency by ≈15 minutes and increases total sleep time by ≈23 minutes in adults with both sleep‑onset and sleep‑maintenance insomnia (moderate‑to‑high evidence). 5, 6, 7
• Eszopiclone 2–3 mg improves both sleep onset and maintenance; evidence for efficacy is of moderate strength. 5, 6
• Zaleplon 10 mg is effective primarily for sleep‑onset insomnia; evidence is less robust than for other BzRAs. 5, 6

Alternative First‑Line Options (Non‑BzRA)

• Ramelteon 8 mg is indicated for sleep‑onset insomnia, offers a favorable safety profile with minimal adverse effects and no risk of dependence (moderate evidence). 5, 6, 8
• Suvorexant 10–20 mg (orexin‑receptor antagonist) is effective for sleep‑maintenance insomnia (moderate evidence). 5, 6, 9

Dosing Considerations for Previously Used Agents

• Doxepin is FDA‑approved for insomnia only at 3 mg or 6 mg; these low doses selectively block H1 receptors to improve sleep maintenance without notable anticholinergic effects (high evidence). 5, 6, 8, 10
• Quetiapine at 300 mg is associated with increased mortality, dementia, and fall risk in older adults; AASM classifies atypical antipsychotics as “other sedating agents” reserved for patients with specific comorbidities. (moderate evidence) 2, 3, 4

Medications Not Recommended

• Trazodone is discouraged for insomnia; randomized data show no meaningful improvement in sleep efficiency versus placebo (MD 1.38 %, 95 % CI ‑2.87 to 5.63) and it carries risks of morning grogginess, dry mouth, and orthostatic hypotension (low‑moderate evidence). 5, 6, 8
• Diphenhydramine – AASM recommends against use due to anticholinergic effects, especially in the elderly (moderate evidence). 5, 10
• Melatonin 2 mg – Evidence for efficacy in chronic insomnia is insufficient (low evidence). 5, 6
• Tiagabine – Explicitly not recommended for insomnia (low evidence). 5, 6
• Benzodiazepines (e.g., diazepam, lorazepam) – Use only as a last resort because the risk of dependence, falls, and cognitive impairment outweighs benefits (moderate evidence). 10

Combination Therapy for Refractory Cases

• When monotherapy with a BzRA is insufficient, the AASM suggests combining a BzRA with properly‑dosed doxepin (3–6 mg) to enhance efficacy while maintaining safety. (moderate evidence) 2, 3, 4

Safety Precautions for BzRAs

• The FDA has issued warnings about complex sleep‑related behaviors (e.g., sleepwalking, sleep‑driving) associated with zolpidem, eszopiclone, and zaleplon; clinicians should counsel patients, prescribe the lowest effective dose, and limit duration of therapy (high evidence). 10

Adjunctive Non‑pharmacologic Therapy

• Cognitive‑behavioral therapy for insomnia (CBT‑I) should be offered alongside any pharmacologic regimen; it improves treatment outcomes and facilitates eventual medication discontinuation (high evidence). 2, 3, 4, 10

AASM 2017 Recommendations for Insomnia Management

First‑Line Pharmacologic Options

• The American Academy of Sleep Medicine (AASM) 2017 guideline recommends orexin‑receptor antagonists (e.g., lemborexant and its predecessor suvorexant) as appropriate therapy for sleep‑maintenance insomnia in adults. 11

Agents Not Recommended as Primary Therapy

• The AASM 2017 insomnia guideline does not list mirtazapine as a recommended treatment for primary insomnia, indicating it lacks guideline support for this indication. 11, 12
• The AASM explicitly advises against the use of trazodone for insomnia, classifying sedating antidepressants as second‑ or third‑line agents that should be reserved for patients with comorbid mood disorders. 11, 13

Adjunctive Non‑Pharmacologic Therapy

• The AASM recommends incorporating cognitive‑behavioral therapy for insomnia (CBT‑I) as an adjunctive strategy to support eventual discontinuation of pharmacologic agents. 12, 13

Management of Insomnia with Nighttime Screaming in Patients on Complex Polypharmacy

Immediate Recommendations

• Discontinue quetiapine immediately and start cognitive‑behavioral therapy for insomnia (CBT‑I) while evaluating the cause of nighttime screaming and optimizing the current medication regimen. [​@1​]

Evidence Supporting CBT‑I as First‑Line Therapy

• The American College of Physicians (ACP) gives a strong recommendation (moderate‑quality evidence) that CBT‑I is the gold‑standard first‑line treatment for chronic insomnia disorder. [​@1​]
• CBT‑I, delivered in‑person, by telephone, via web‑based modules, or self‑help books, improves sleep onset latency, wake after sleep onset, sleep efficiency, and overall sleep quality without the adverse effects associated with pharmacotherapy. [​@2​]

Pharmacologic Options When CBT‑I Is Insufficient (AASM 2017 Recommendations)

• Sleep‑onset insomnia:
  
  • Zolpidem 10 mg (maximum FDA‑approved dose) can be added after 4–6 weeks of CBT‑I if needed. [​@3​]
  • Ramelteon 8 mg nightly is an alternative with no dependence risk and a favorable safety profile. [​@3​]
• Sleep‑maintenance insomnia:
  
  • Eszopiclone 2–3 mg nightly is recommended. [​@3​]
  • Suvorexant 10–20 mg nightly (orexin antagonist) has favorable long‑term safety. [​@3​]
  • Low‑dose doxepin 3–6 mg nightly (selective H₁ blockade) is FDA‑approved for insomnia and avoids anticholinergic effects at this dose. [​@3​]
• Second‑line benzodiazepine (if all other agents fail):
  
  • Temazepam 15 mg (higher doses provide no additional benefit) is the AASM‑recommended benzodiazepine for refractory cases. [​@3​]

Agents to Avoid in Insomnia Management

• Trazodone – yields only a 1.38 % improvement in sleep efficiency versus placebo (95 % CI −2.87 to 5.63) and commonly causes morning grogginess, dry mouth, and orthostatic hypotension. [​@3​]
• Diphenhydramine and other antihistamines – lack efficacy data for insomnia and carry anticholinergic adverse effects. [​@3​][​@5​]
• Supratherapeutic zolpidem doses (>10 mg) – off‑label, unsupported by evidence, and associated with FDA black‑box warnings for complex sleep behaviors. [​@3​]

Monitoring Plan

• Conduct weekly assessments during the first month to evaluate sleep quality, frequency of nighttime screaming, and medication tolerability. [​@3​]
• After the first month, switch to monthly monitoring for adverse effects (falls, cognitive impairment, complex sleep behaviors), perform pill counts, and obtain urine drug screens when prescribing controlled substances.

Key Pitfalls to Avoid

• Do not omit CBT‑I; it is the only treatment with a strong recommendation and should be offered to all patients with chronic insomnia. [​@1​][​@2​][​@4​]